Juha Veijola Selected Research

Mental Disorders (Mental Disorder)

1/2020	Frequent intoxication and alcohol tolerance in adolescence: associations with psychiatric disorders in young adulthood.
11/2014	Neuropeptide precursor VGF is genetically associated with social anhedonia and underrepresented in the brain of major mental illness: its downregulation by DISC1.
1/2012	DISC1 conditioned GWAS for psychosis proneness in a large Finnish birth cohort.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juha Veijola Research Topics

Disease

13	Schizophrenia (Dementia Praecox) 01/2022 - 08/2005
9	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 06/2004
3	Mental Disorders (Mental Disorder) 01/2020 - 01/2012
2	Cognitive Dysfunction 06/2021 - 08/2017
2	Bipolar Disorder (Manic Depressive Psychosis) 10/2017 - 11/2014
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 05/2016 - 08/2015
1	Neurodevelopmental Disorders 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Pain (Aches) 01/2022
1	Postpartum Depression (Post-Natal Depression) 02/2020
1	Borderline Personality Disorder (Personality Disorders, Borderline) 02/2020
1	Disease Susceptibility (Diathesis) 01/2017
1	Liver Diseases (Liver Disease) 12/2015
1	Hypertension (High Blood Pressure) 12/2015
1	Obesity 12/2015
1	Anhedonia 11/2014
1	Weight Gain 01/2014
1	Lung Neoplasms (Lung Cancer) 12/2013
1	Tobacco Use Disorder (Nicotine Dependence) 12/2013
1	Facial Pain (Myofacial Pain) 05/2013
1	Chronic Disease (Chronic Diseases) 10/2012
1	Mood Disorders (Mood Disorder) 08/2011
1	Prodromal Symptoms 01/2011
1	Pathologic Processes 03/2010
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2006
1	Intellectual Disability (Idiocy) 06/2003

Drug/Important Bio-Agent (IBA)

5	Antipsychotic Agents (Antipsychotics)IBA 08/2017 - 01/2014
3	Biological ProductsIBA 05/2016 - 01/2012
2	C-Reactive ProteinIBA 01/2021 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2020 - 08/2015
2	Cytochrome P-450 CYP2B1 (PROD)IBA 11/2018 - 01/2011
2	Dopamine Receptors (Dopamine Receptor)IBA 01/2015 - 08/2011
2	Indicators and Reagents (Reagents)IBA 08/2005 - 06/2004
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2022
1	Sp4 Transcription FactorIBA 01/2022
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 06/2021
1	Complement System Proteins (Complement)IBA 06/2021
1	4-aminospiroperidolIBA 02/2020
1	Biological FactorsIBA 10/2017
1	BenzodiazepinesIBA 08/2017
1	GlucocorticoidsIBA 01/2017
1	Histones (Histone)IBA 04/2016
1	LipidsIBA 12/2015
1	Uncoupling Protein 2IBA 12/2015
1	Ethanol (Ethyl Alcohol)IBA 12/2015
1	Alanine Transaminase (SGPT)IBA 12/2015
1	TransferasesIBA 12/2015
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2015
1	Antidepressive Agents (Antidepressants)IBA 11/2014
1	NeuropeptidesIBA 11/2014
1	Chlorpromazine (Thorazine)FDA Link 01/2014
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 12/2013
1	CotinineIBA 12/2013
1	Pain-FreeIBA 05/2013
1	AntibodiesIBA 10/2012
1	EpitopesIBA 10/2012
1	ProteomeIBA 10/2012
1	Proteins (Proteins, Gene)FDA Link 10/2012
1	Neuregulin-1 (Neuregulin 1)IBA 02/2012
1	Biomarkers (Surrogate Marker)IBA 03/2010
1	A 7 (A-7)IBA 11/2009
1	CholesterolIBA 03/2006

Therapy/Procedure

1	Surgical Instruments (Clip) 08/2015
1	Duration of Therapy 06/2003